Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension
NCT00710372
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
83
Enrollment
INDUSTRY
Sponsor class
Conditions
Mild Essential Hypertension
Moderate Essential Hypertension
Interventions
BIOLOGICAL:
CYT006-AngQb
Sponsor
Cytos Biotechnology AG